menu search

QLGN / Qualigen Therapeutics' Partner NanoSynex to Present Technology at BioMed Israel

Qualigen Therapeutics' Partner NanoSynex to Present Technology at BioMed Israel
Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold Read More
Posted: May 10 2022, 09:17
Author Name: GlobeNewsWire
Views: 111674

QLGN News  

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

By GlobeNewsWire
March 15, 2023

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

CARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified li more_horizontal

Qualigen Therapeutics' Partner NanoSynex to Present Technology at BioMed Israel

By GlobeNewsWire
May 10, 2022

Qualigen Therapeutics' Partner NanoSynex to Present Technology at BioMed Israel

Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold more_horizontal

Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today

By PennyStocks
April 12, 2022

Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today

Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on P more_horizontal

Qualigen Surges 80% As QN-302 Shows Potential Preclinical Mechanism Of Action Against Prostate, Pancreatic Cancers

By Benzinga
April 12, 2022

Qualigen Surges 80% As QN-302 Shows Potential Preclinical Mechanism Of Action Against Prostate, Pancreatic Cancers

Qualigen Therapeutics Inc (NASDAQ: QLGN) shares are surging after highlighting posters at the American Association of Cancer Research (AACR). QN-302� more_horizontal


Search within

Pages Search Results: